Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Arcellx, Inc. (ACLX)
:ACLX
Holding ACLX?
Track your performance easily
ACLX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$47.88 - $107.37
Previous CloseN/A
Volume227.93K
Average Volume (3M)656.89K
Market Cap
$3.62B
Enterprise Value$3.99B
Total Cash (Recent Filing)$46.60M
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta2.21
Next Earnings
Mar 20, 2025EPS Estimate
-0.55Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.74
Shares Outstanding54,074,670
10 Day Avg. Volume760,844
30 Day Avg. Volume656,893
Standard Deviation0.21
R-Squared0.00620
Alpha0.06
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)23.43
Price to Cash Flow (P/CF)29.70
P/FCF Ratio32.10
Enterprise Value/Market Cap1.10
Enterprise Value/Revenue25.58
Enterprise Value/Gross Profit36.13
Enterprise Value/Ebitda-137.47
Forecast
1Y Price Target
$114.85Price Target Upside71.39% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering16
Arcellx Inc News
PremiumCompany Announcements
Arcellx, Inc. Reports Q3 2024 Earnings Highlights
Bulls Say, Bears Say
Bulls Say
Clinical Trial ComparisonsPhase 2 iMMagine-1 data is comparable to CARTITUDE-1 and is expected to improve over time, with progression-free survival likely to separate.
Commercial Market PotentialThe opportunity for anito-cel to commercialize through Kite manufacturing, with a quick turnaround time, is seen as a differentiator in the commercial market.
Product Efficacy And SafetyThe presentation reinforced appreciation for the product’s efficacy and safety.
Bears Say
Commercial ChallengesBroader CAR-T commercial challenges add some risk to revenue and profit expectations.
Investor SentimentACLX shares are down, seen as a 'sell the news' reaction despite positive abstract data.
Safety ConcernsThree deaths occurred due to adverse events, highlighting potential risks despite the positive outcomes.
---
Ownership Overview
3.06% Insiders
25.03% Mutual Funds
0.06% Other Institutional Investors
59.25% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ACLX FAQ
What was Arcellx, Inc.’s price range in the past 12 months?
Arcellx, Inc. lowest stock price was $47.88 and its highest was $107.37 in the past 12 months.
What is Arcellx, Inc.’s market cap?
Arcellx, Inc.’s market cap is $3.62B.
When is Arcellx, Inc.’s upcoming earnings report date?
Arcellx, Inc.’s upcoming earnings report date is Mar 20, 2025 which is in 61 days.
How were Arcellx, Inc.’s earnings last quarter?
Arcellx, Inc. released its earnings results on Nov 07, 2024. The company reported -$0.48 earnings per share for the quarter, missing the consensus estimate of -$0.31 by -$0.17.
Is Arcellx, Inc. overvalued?
According to Wall Street analysts Arcellx, Inc.’s price is currently Undervalued.
Does Arcellx, Inc. pay dividends?
Arcellx, Inc. does not currently pay dividends.
What is Arcellx, Inc.’s EPS estimate?
Arcellx, Inc.’s EPS estimate is -0.55.
How many shares outstanding does Arcellx, Inc. have?
Arcellx, Inc. has 54,074,670 shares outstanding.
What happened to Arcellx, Inc.’s price movement after its last earnings report?
Arcellx, Inc. reported an EPS of -$0.48 in its last earnings report, missing expectations of -$0.31. Following the earnings report the stock price went up 3.933%.
Which hedge fund is a major shareholder of Arcellx, Inc.?
Currently, no hedge funds are holding shares in ACLX
---
Arcellx Inc Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$114.85 (71.39% Upside)
$114.85 (71.39% Upside)
Blogger Sentiment
Bullish
ACLX Sentiment 70%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 247.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 2.8%
Last 30 Days ▲ 12.2%
Last 30 Days ▲ 12.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
22.39%
12-Months-Change
Fundamentals
Return on Equity
-10.79%
Trailing 12-Months
Asset Growth
24.53%
Trailing 12-Months
Company Description
Arcellx, Inc.
Arcellx Inc is a clinical-stage biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases.
---
ACLX Stock 12 Month Forecast
Average Price Target
$114.85
▲(71.39% Upside)
Technical Analysis
Adaptimmune Therapeutics
―
ALX Oncology Holdings
―
Immatics
―
Cabaletta Bio
―
Intellia Therapeutics
―
Voyager Therapeutics
―
Best Analysts Covering ACLX
1 Year
1 Year Success Rate
11/13 ratings generated profit
1 Year Average Return
+49.20%
assigned a buy rating 2 months ago
Copying Jack Allen's trades and holding each position for 1 Year would result in 84.62% of your transactions generating a profit, with an average return of +49.20% per trade.
---